<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941103-1-00007</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 --> 6. Should there be quality assurance checks and measurements for remote afterloading brachytherapy devices, in 10 CFR Part 35, as there are for teletherapy? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> If no, why not? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 7. Are there existing standards on calibration of brachytherapy sources? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> If yes, or yes in part, what are these standards? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 8. What types of tests/checks do you perform at source exchange? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 9. a. Should there be training and experience criteria established for brachytherapy physicists involved with HDR treatment planning? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> b. Should there be training and experience criteria established for brachytherapy physicians performing HDR treatments? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 10. What procedures do you follow to ensure proper placement of brachytherapy implants (e.g., do you use X-ray films for verification)? What is the standard of care with respect to proper placement of brachytherapy implants? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Manual Brachytherapy <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 11. NRC regulations require that the written directive for all brachytherapy, other than high-dose-rate remote afterloading brachytherapy, include: (i) prior to implantation: the radioisotope, number of sources, and source strengths; and (ii) after implantation, but prior to completion of the procedure: the radioisotope, treatment site, and total source strength and exposure time (or equivalently, the total dose). What additional information do you typically include on the written directive and why? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Prior to implantation: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> After implantation: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 12. a. Do you order sources in writing? <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No, ordered by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XXX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->   <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> b. Who usually orders sources at your facility? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 13. a. Do you verify the activity of sources: <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Upon receipt <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Prior to implantation <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Not at all  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> b. If yes, how is the activity verified? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> c. Who typically verifies the source activity at your facility? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 14. a. What procedures do you follow to ensure proper placement of brachytherapy implants? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> b. What actions do you take to prevent or minimize the likelihood of brachytherapy sources moving after implantation? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 15. Are existing standards and procedures adequate to ensure that the source is positioned and, consequently, the treatment is in accordance with the direction of the authorized user? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 16. In your experience, what is the most effective means for accomplishing training of nurses as required in 10 CFR 35.410 and 35.25? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 17. Do you believe that all nurses handling brachytherapy patients at your facility have received adequate training? <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 18. For permanent prostate implants, what do you consider to be an acceptable percentage of implanted seeds outside the target volume? <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  percent  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> What is the current accepted standard of practice? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Radiopharmaceutical Therapy <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 19. NRC regulations require that the written directive, for radiopharmaceutical therapy, include the radiopharmaceutical, dosage, and route of administration. What additional information do you typically include in your written directives, and why? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 20. If more than one fraction is to be administered, should the written directive be prepared to include the specifics for the entire course of therapy or should a written directive be prepared for each individual fraction? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 21. Do you typically prepare separate written directives for fractionated radiopharmaceutical therapy? <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=16 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  Yes&blank;&blank; <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=7 f=2 --> XX <!-- PJG /ITAG -->  <!-- PJG ITAG l=16 g=1 f=1 -->  No  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 22. Where would you seek guidance (if needed) on the radiation safety aspects of radiopharmaceutical therapy (use of unsealed sources)? <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 23. Do you have any additional comments or specific issues regarding NRC's regulation of therapeutic uses of byproduct material? <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated at Rockville, Maryland, this 28th day of October, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> For the Nuclear Regulatory Commission. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> John E. Glenn, <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Chief, Medical, Academic, and Commercial Use Safety Branch, Division of Industrial and Medical Nuclear Safety, Office of Nuclear Material Safety and Safeguards. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;27250 Filed 11&hyph;2&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 7590&hyph;01&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            